Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Regadenoson Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 14/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 6/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regadenoson Anhydrous SCHEMBL19387116 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL20128455 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL14131217 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL12958830 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL8925057 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL278152 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL13462149 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL15472806 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL6745611 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL21710782 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301973-A1 | TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA | FLOHIL JACOB ARY (NL) | 2023-09-28 | — | — | US | claimed |
| WO-2018106118-A1 | TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA | FLOHIL JACOB ARY (NL) | 2018-06-14 | — | — | WO | claimed |
| US-11535644-B2 | Solid-state forms of Regadenoson, their use and preparation | MACFARLAN SMITH LIMITED (GB) | 2022-12-27 | — | — | US | disclosed |
| US-10953015-B2 | Use of adenosine receptor signaling to regulate P-gp function | CORNELL UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210009626-A1 | SOLID-STATE FORMS OF REGADENOSON, THEIR USE AND PREPARATION | MACFARLAN SMITH LIMITED (GB) | 2021-01-14 | — | — | US | disclosed |
| US-20190038630-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO REGULATE P-GP FUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-07 | — | — | US | disclosed |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | The united States of America,as represented by Secretary,Dept.,of Health and Human Services (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2011123518-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535644-B2 | Solid-state forms of Regadenoson, their use and preparation | CYP2D6, MGMT, MRPS27 | ADORA2A 809/4885ADORA3 723/4885ADORA1 1175/4885 |
| US-20230301973-A1 | TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA | ABCC2, SLC2A2, ABCB1 | ADORA2A 242/4885ADORA3 903/4885ADORA1 1385/4885 |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | NT5E, NT5C2, NT5C3B | ADORA2A 4/4885ADORA3 6/4885ADORA1 9/4885 |
| US-20210009626-A1 | SOLID-STATE FORMS OF REGADENOSON, THEIR USE AND PREPARATION | CYP2D6, MGMT, MRPS27 | ADORA2A 809/4885ADORA3 723/4885ADORA1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.